- R-(+)-Lansoprazole
-
- US $1.00-1.00 / Kg/Bag
- 2020-05-12
- CAS:138530-94-6
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50tons
- R-(+)-Lansoprazole
-
- US $200.00 / KG
- 2019-07-06
- CAS:138530-94-6
- Min. Order: 100G
- Purity: 98%
- Supply Ability: 200KG
|
| | R-(+)-Lansoprazole Basic information |
| Product Name: | R-(+)-Lansoprazole | | Synonyms: | Lansoprazole Impurity 14;Dexlansoprazole related impurities 2;(R)-2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole;1H-Benzimidazole, 2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI);1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-, (R)-;R-(+)-Lansoprazole;Dexlansoprazole;2-[(R)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole | | CAS: | 138530-94-6 | | MF: | C16H14F3N3O2S | | MW: | 369.36 | | EINECS: | 1308068-626-2 | | Product Categories: | DEXILANT;APIs;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds | | Mol File: | 138530-94-6.mol |  |
| | R-(+)-Lansoprazole Chemical Properties |
| Melting point | 66-68?C | | Boiling point | 555.8±60.0 °C(Predicted) | | density | 1.50±0.1 g/cm3(Predicted) | | storage temp. | Refrigerator | | pka | 9.56±0.10(Predicted) |
| | R-(+)-Lansoprazole Usage And Synthesis |
| Description | The mechanism of PPIs involves the irreversible binding to the hydrogen/potassium adenosine triphosphatase enzyme system, commonly
referred to as the gastric proton pump, of the gastric parietal cell. As
the last stage in gastric acid secretion, blockade of the gastric proton
pump is an effective treatment for a variety of diseases requiring acid suppression, such as heartburn, peptic ulcers, and GERD. Dexlansoprazole is the latest PPI to hit the market, joining the ranks of omeprazole,
rabeprazole, pantoprazole, esomeprazole, and lansoprazole, and is the Renantiomer of the racemic lansoprazole. Compared to its predecessors,
dexlansoprazole exhibits improved pharmacokinetics with slower clearance and longer terminal half-life. In addition, dexlansoprazole utilizes a
novel DDR technology; drug release is optimized through the use of
granules with different pH-dependent dissolution profiles, thereby providing an initial release in the proximal small intestine within 1-2 h of
administration followed by a subsequent release at distal regions of the
small intestine several hours later. With its longer duration of action
culminating in more effective acid suppression, dexlansoprazole may
have an advantage over conventional PPIs that possess single release
formulations (immediate or delayed).
Similar to all PPIs, dexlansoprazole
is a prodrug that consists of pyridine and benzimidazole rings with a
latent sulfenamide moiety. In order to form the disulfide bond with
cysteine residues of the proton pump, dexlansoprazole must be activated
through two protonations followed by a spontaneous rearrangement to
unmask the sulfenamide. | | Chemical Properties | Brown Solid | | Originator | Takeda (Japan) | | Uses | The R-enantiomer of Lansoprazole; a gastric proton pump inhibitor. An antiulcerative | | Uses | antiulcer, proton pump inhibitor | | Uses | Acts as a gastric proton pump inhibitor and an antiulcerative | | Brand name | Kapidex | | Side effects | The most commonly recorded adverse reactions that occurred at a higher incidence than placebo were diarrhea, abdominal pain, nausea, vomiting, flatulence, and upper respiratory tract infection. As dexlansoprazole inhibits gastric acid secretion, its use is expected to interfere with the absorption of drugs with pH-dependent oral bioavailability. Since the HIV protease inhibitor atazanavir is dependent on gastric acid for absorption, dexlansoprazole should not be co-administered with atazanavir to avoid a loss of therapeutic efficacy. While co-administration of dexlansoprazole did not affect the pharmacokinetics of warfarin or INR (international normalized ratio: the ratio of a patient s prothrombin time to a normal sample), there have been reports of increased INR and prothrombin time in patients receiving concomitant treatment with PPIs and warfarin. Since increases in INR and prothrombin time may lead to abnormal bleeding and possibly death, concomitant use of dexlansoprazole and warfarin may necessitate monitoring for increases in INR and prothrombin time. |
| | R-(+)-Lansoprazole Preparation Products And Raw materials |
|